Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma NCT00019708 Extranodal Marg...
Nodal Marginal ...
Non-Hodgkin Lym...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
tanespimycin
19 Years - National Cancer Institute (NCI) View Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 Acute Lymphobla...
Acute Myeloid L...
Aggressive Non-...
Chronic Myeloge...
Chronic Phase C...
Indolent Non-Ho...
Lymphoma
Mixed Phenotype...
Myelodysplastic...
Myeloproliferat...
Recurrent Chron...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Plasm...
Recurrent Small...
Recurrent T-Cel...
Refractory Chro...
Refractory Chro...
Refractory Foll...
Refractory Hodg...
Refractory Lymp...
Refractory Mant...
Refractory Smal...
T-Cell Non-Hodg...
Allogeneic Hema...
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Total-Body Irra...
Umbilical Cord ...
- 69 Years Fred Hutchinson Cancer Center View Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation NCT00003056 Leukemia
Lymphoma
Graft Versus Ho...
cyclosporine
cyclosporine an...
18 Years - 55 Years Takeda View Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer NCT00546377 Leukemia
Lymphoma
filgrastim
pegfilgrastim
rituximab
sargramostim
cyclophosphamid...
mitoxantrone hy...
pentostatin
fluorescence in...
gene rearrangem...
polymerase chai...
protein express...
flow cytometry
biopsy
18 Years - 120 Years Memorial Sloan Kettering Cancer Center View Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268 B-Cell Prolymph...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Richter Syndrom...
Ibrutinib
Laboratory Biom...
Pevonedistat
Pharmacokinetic...
Pharmacological...
18 Years - City of Hope Medical Center View Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease NCT00176475 Leukemia
Lymphoma
Multiple Myelom...
rituximab
therapeutic all...
18 Years - Rutgers, The State University of New Jersey View Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation NCT00003143 Lymphoma
Amifostine
DHAP
18 Years - Jonsson Comprehensive Cancer Center View Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma NCT00244946 Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 Years Barbara Ann Karmanos Cancer Institute View Bone Marrow Transplantation in Treating Patients With Lymphoma NCT00002829 Lymphoma
Recombinant Int...
Cyclophosphamid...
Etoposide
Mesna
Bone Marrow Tra...
Radiation Thera...
15 Years - 60 Years M.D. Anderson Cancer Center View Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma NCT00538187 Adult Non-Hodgk...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
obatoclax mesyl...
bortezomib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI) View Beta Alethine in Treating Patients With Low-Grade Lymphoma NCT00007839 Lymphoma
beta alethine
18 Years - National Cancer Institute (NCI) View Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00119392 B-cell Chronic ...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Waldenström Mac...
rituximab
cyclosporine
fludarabine pho...
mycophenolate m...
yttrium Y 90 ib...
peripheral bloo...
allogeneic hema...
total-body irra...
18 Years - Fred Hutchinson Cancer Center View Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma NCT00017381 Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Extranodal Marg...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Stage I Adult D...
Stage I Adult D...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenström Mac...
rituximab
cyclophosphamid...
filgrastim
yttrium Y 90 ib...
peripheral bloo...
18 Years - 70 Years National Cancer Institute (NCI) View Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma NCT01381692 Recurrent Folli...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Recurrent Walde...
Refractory Foll...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Bortezomib
Dexamethasone
Laboratory Biom...
Quality-of-Life...
Rituximab
Temsirolimus
18 Years - National Cancer Institute (NCI) View Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma NCT00980395 Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona View Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma NCT00265928 Lymphoma
bortezomib
rituximab
antibody therap...
biological ther...
enzyme inhibito...
monoclonal anti...
18 Years - National Cancer Institute (NCI) View SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma NCT00101244 Adult Grade III...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
ispinesib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI) View Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202 NCT00896662 Lymphoma
Solid Tumor
immunologic tec...
laboratory biom...
pharmacological...
18 Years - Vanderbilt-Ingram Cancer Center View Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases NCT00376519 Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
Secondary Myelo...
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
Treg cell infus...
umbilical cord ...
total-body irra...
18 Years - 45 Years Masonic Cancer Center, University of Minnesota View Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma NCT00397800 Lymphoma
rituximab
cyclophosphamid...
fludarabine pho...
yttrium Y 90 ib...
50 Years - 75 Years Technical University of Munich View Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma NCT00005601 Lymphoma
rituximab
cisplatin
cytarabine
dexamethasone
sargramostim
18 Years - Alliance for Clinical Trials in Oncology View Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00007852 Lymphoma
rituximab
carmustine
cytarabine
etoposide
melphalan
autologous hema...
19 Years - University of Nebraska View Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma NCT00006039 Lymphoma
Small Intestine...
pegylated inter...
18 Years - Memorial Sloan Kettering Cancer Center View Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma NCT04659044 Recurrent B-Cel...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory B-Ce...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Mant...
Refractory Marg...
Refractory Smal...
Polatuzumab Ved...
Rituximab
Rituximab and H...
Venetoclax
18 Years - Academic and Community Cancer Research United View Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma NCT00278161 Leukemia
Lymphoma
Pegfilgrastim
Rituximab
Cyclophosphamid...
18 Years - 70 Years Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins View Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy NCT00891137 Leukemia
Lymphoma
Multiple Myelom...
Plasma Cell Neo...
Myelodysplastic...
human myeloid p...
12 Years - 65 Years Cellerant Therapeutics View Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma NCT00004192 Lymphoma
Neutropenia
filgrastim
pegfilgrastim
cisplatin
cytarabine
etoposide
methylprednisol...
18 Years - 120 Years University of Nebraska View Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers NCT00003163 Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI) View Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function NCT00118170 Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI) View Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma NCT00007865 Lymphoma
rituximab
carboplatin
etoposide
ifosfamide
19 Years - 120 Years University of Nebraska View Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma NCT00002697 Lymphoma
filgrastim
sargramostim
carboplatin
etoposide
ifosfamide
autologous bone...
bone marrow abl...
peripheral bloo...
radiation thera...
18 Years - 65 Years Memorial Sloan Kettering Cancer Center View Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00244985 Lymphoma
rituximab
pegylated lipos...
18 Years - 120 Years Roswell Park Cancer Institute View Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer NCT00003661 Graft Versus Ho...
Leukemia
Lymphoma
Myelodysplastic...
Neuroblastoma
anti-thymocyte ...
busulfan
cyclosporine
melphalan
methylprednisol...
umbilical cord ...
radiation thera...
- 54 Years Roswell Park Cancer Institute View Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma NCT00026429 Leukemia
Lymphoma
denileukin dift...
18 Years - National Cancer Institute (NCI) View Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma NCT01812005 Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
alisertib
rituximab
laboratory biom...
18 Years - Ohio State University Comprehensive Cancer Center View Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation NCT00003143 Lymphoma
Amifostine
DHAP
18 Years - Jonsson Comprehensive Cancer Center View Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma NCT00082823 Cancer
ziv-aflibercept
18 Years - 120 Years Regeneron Pharmaceuticals View Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies NCT04205409 Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Non-H...
Recurrent Plasm...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Marg...
Refractory Non-...
Refractory Plas...
Recurrent Mantl...
Refractory Mant...
Nivolumab
18 Years - University of Washington View Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia NCT00002908 Leukemia
Lymphoma
bryostatin 1
vincristine sul...
18 Years - Barbara Ann Karmanos Cancer Institute View Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT02992522 B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Margi...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Transformed Rec...
B-Cell
Lenalidomide
Obinutuzumab
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center View Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT02992522 B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Margi...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Transformed Rec...
B-Cell
Lenalidomide
Obinutuzumab
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center View Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma NCT00003356 Lymphoma
aldesleukin
rituximab
18 Years - 75 Years University of Rochester View Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) NCT00005626 Leukemia
Lymphoma
Irinotecan
18 Years - H. Lee Moffitt Cancer Center and Research Institute View Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia NCT00017472 Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Margi...
Recurrent Small...
Refractory Chro...
Splenic Margina...
Stage III Margi...
Stage III Small...
Stage IV Margin...
Stage IV Small ...
apolizumab
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI) View Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268 B-Cell Prolymph...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Richter Syndrom...
Ibrutinib
Laboratory Biom...
Pevonedistat
Pharmacokinetic...
Pharmacological...
18 Years - City of Hope Medical Center View Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia NCT00005786 Extranodal Marg...
Nodal Marginal ...
Prolymphocytic ...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Refractory Chro...
Splenic Margina...
Waldenström Mac...
arsenic trioxid...
laboratory biom...
18 Years - National Cancer Institute (NCI) View Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function NCT00118170 Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI) View Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome NCT00002989 Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
busulfan
cyclophosphamid...
idarubicin
melphalan
radiation thera...
16 Years - 60 Years National Cancer Institute (NCI) View Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00040950 Lymphoma
rituximab
agatolimod sodi...
18 Years - National Cancer Institute (NCI) View Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia NCT00062296 Leukemia
Lymphoma
rituximab
epirubicin hydr...
18 Years - Fox Chase Cancer Center View Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma NCT00691652 Lymphoma
rituximab
clofarabine
DNA methylation...
gene expression...
microarray anal...
polymerase chai...
high performanc...
laboratory biom...
18 Years - 89 Years OHSU Knight Cancer Institute View Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT01045928 Adult Non-Hodgk...
Adult Grade III...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage I Adult B...
Stage I Adult D...
Stage I Adult D...
Stage I Adult D...
Stage I Adult I...
Stage I Adult L...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenstrom Mac...
lenalidomide
rituximab
polymerase chai...
nucleic acid se...
polymorphism an...
flow cytometry
laboratory biom...
18 Years - Case Comprehensive Cancer Center View UCN-01 in Treating Patients With Advanced Cancer NCT00003289 Leukemia
Lymphoma
Unspecified Adu...
7-hydroxystauro...
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins View Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00110071 Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
fludarabine pho...
peripheral bloo...
iodine I 131 to...
laboratory biom...
flow cytometry
polymerase chai...
60 Years - Fred Hutchinson Cancer Center View Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer NCT00010192 B-cell Adult Ac...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
rituximab
aldesleukin
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI) View Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma NCT00002779 Lymphoma
fludarabine pho...
octreotide acet...
18 Years - Alliance for Clinical Trials in Oncology View Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma NCT02281279 B-cell Adult Ac...
Extranodal Marg...
Intraocular Lym...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Hair...
Small Intestine...
Splenic Margina...
Testicular Lymp...
Waldenström Mac...
rituximab
lenalidomide
romidepsin
laboratory biom...
18 Years - Mayo Clinic View Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma NCT04635683 Recurrent B-Cel...
Recurrent Extra...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Nodal...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Extr...
Refractory Foll...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Noda...
Refractory Sple...
Refractory Wald...
Lenalidomide
Ublituximab
Umbralisib
18 Years - Ohio State University Comprehensive Cancer Center View PS-341 in Treating Patients With Advanced Cancer NCT00006362 Leukemia
Lymphoma
Multiple Myelom...
Precancerous Co...
Unspecified Adu...
bortezomib
18 Years - Mayo Clinic View Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy NCT00003341 Anemia
Leukemia
Lymphoma
Multiple Myelom...
epoetin alfa
quality-of-life...
18 Years - Memorial Sloan Kettering Cancer Center View Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma NCT00006252 Leukemia
Lymphoma
fludarabine pho...
Cyclophosphamid...
PBSC
G-CSF
Donor lymphocyt...
- 69 Years Alliance for Clinical Trials in Oncology View Bone Marrow Transplantation in Treating Patients With Lymphoma NCT00002829 Lymphoma
Recombinant Int...
Cyclophosphamid...
Etoposide
Mesna
Bone Marrow Tra...
Radiation Thera...
15 Years - 60 Years M.D. Anderson Cancer Center View Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00005592 Lymphoma
90-Y-ibritumoma...
rituximab
indium In 111 i...
18 Years - University of Alabama at Birmingham View Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma NCT02049541 Extranodal Marg...
Nodal Marginal ...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
PI3K inhibitor ...
rituximab
Pharmacodynamic...
Correlative stu...
18 Years - Ohio State University Comprehensive Cancer Center View Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00040950 Lymphoma
rituximab
agatolimod sodi...
18 Years - National Cancer Institute (NCI) View Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer NCT00003661 Graft Versus Ho...
Leukemia
Lymphoma
Myelodysplastic...
Neuroblastoma
anti-thymocyte ...
busulfan
cyclosporine
melphalan
methylprednisol...
umbilical cord ...
radiation thera...
- 54 Years Roswell Park Cancer Institute View Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00110071 Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
fludarabine pho...
peripheral bloo...
iodine I 131 to...
laboratory biom...
flow cytometry
polymerase chai...
60 Years - Fred Hutchinson Cancer Center View Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00073918 Anaplastic Larg...
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
cyclophosphamid...
etoposide
iodine I 131 to...
quality-of-life...
peripheral bloo...
18 Years - 60 Years Fred Hutchinson Cancer Center View Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma NCT00551239 Leukemia
Lymphoma
rituximab
fludarabine pho...
pixantrone dima...
18 Years - 120 Years CTI BioPharma View Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma NCT00980395 Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona View Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas NCT02332980 Recurrent B-Cel...
Recurrent Chron...
Recurrent Extra...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Margi...
Recurrent Nodal...
Recurrent Small...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Chro...
Refractory Extr...
Refractory Foll...
Refractory Lymp...
Refractory Noda...
Refractory Smal...
Refractory Sple...
Refractory Wald...
Richter Syndrom...
Waldenstrom Mac...
Ibrutinib
Idelalisib
Laboratory Biom...
Pembrolizumab
18 Years - Mayo Clinic View UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia NCT00019838 Leukemia
Lymphoma
7-hydroxystauro...
fludarabine pho...
18 Years - National Cancer Institute (NCI) View Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms NCT00082784 Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Refractory Plas...
Splenic Margina...
Waldenstrom Mac...
Bortezomib
Alvocidib Hydro...
Pharmacological...
18 Years - National Cancer Institute (NCI) View Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers NCT00003163 Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI) View Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma NCT00004192 Lymphoma
Neutropenia
filgrastim
pegfilgrastim
cisplatin
cytarabine
etoposide
methylprednisol...
18 Years - 120 Years University of Nebraska View Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia NCT00004107 Leukemia
Lymphoma
filgrastim
autologous bone...
peripheral bloo...
indium In 111 m...
yttrium Y 90 ep...
18 Years - 80 Years Garden State Cancer Center at the Center for Molecular Medicine and Immunology View Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia NCT00275080 Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Blastic Phase C...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Secondary Acute...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Untreated Adult...
Untreated Adult...
vorinostat
decitabine
18 Years - National Cancer Institute (NCI) View Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00012298 Extranodal Marg...
Nodal Marginal ...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Waldenström Mac...
rituximab
yttrium Y 90 ib...
indium In 111 i...
oprelvekin
filgrastim
18 Years - National Cancer Institute (NCI) View Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma NCT00621452 B-cell Chronic ...
Extranodal Marg...
Nodal Marginal ...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Chro...
Splenic Margina...
Waldenström Mac...
therapeutic aut...
cyclophosphamid...
aldesleukin
polymerase chai...
gene rearrangem...
lymph node biop...
genetically eng...
bone marrow asp...
flow cytometry
laboratory biom...
enzyme-linked i...
- Fred Hutchinson Cancer Center View Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma NCT02049541 Extranodal Marg...
Nodal Marginal ...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
PI3K inhibitor ...
rituximab
Pharmacodynamic...
Correlative stu...
18 Years - Ohio State University Comprehensive Cancer Center View